



**Amirhossein Sahebkar (Pharm.D., Ph.D., FESC)**

Is a Professor at the Department of Biotechnology and the Biotechnology Research Center of Mashhad University of Medical Sciences (Mashhad, Iran). He also holds adjunct titles at Saveetha University (India) and the University of Western Australia (Australia). His research primarily focuses on novel therapeutic strategies for cardiometabolic diseases, encompassing both basic and clinical studies. Dr. Sahebkar is the national lead investigator for the European Atherosclerosis Society FHSC committee in Iran, a global initiative aimed at identifying and improving the care of patients with familial hypercholesterolemia.

Dr. Sahebkar has received numerous research and scientific awards, including being named the most outstanding researcher of the decade in Iran by the Iran Academy of Medical Sciences. He serves on the editorial board of numerous national and international scientific journals. Clarivate Analytics ranked him among the top 1% of cited researchers worldwide in seven distinct scientific fields. He has published over 2,000 articles in peer-reviewed biomedical journals, garnering over 150,000 citations, according to Scopus statistics.